计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
M333473-5mg |
5mg |
现货 ![]() |
| |
M333473-10mg |
10mg |
现货 ![]() |
| |
M333473-25mg |
25mg |
现货 ![]() |
| |
M333473-50mg |
50mg |
现货 ![]() |
| |
M333473-100mg |
100mg |
现货 ![]() |
|
别名 | 6-[(3-氨基苯基)甲基]-4,6-二氢-4-甲基-2-(甲基亚磺酰)-5H-噻吩并吡咯并哒嗪-5-酮 |
---|---|
英文别名 | AS-16621 | CS-4865 | MLS006010294 | A901578 | [6-(3-Aminobenzyl)-4-methyl-5-oxo-5,6-dihydro-4H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-2-yl](methyl)sulfoniumolate | DB01996 | FT-0663861 | 2-METHYLPYRIDINE [HSDB] | 4-methyl morpholine | ML265 | ML-265 | S |
规格或纯度 | Moligand™, ≥98% |
英文名称 | ML 265 |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
作用类型 | 激活剂 |
作用机制 | 丙酮酸激酶 M1/2 激活剂 |
IC50 | activates tumor-specifIC₅₀KM2: EC5050 = 92 nM |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
PubChem SID | 488200983 |
---|---|
分子类型 | 小分子 |
IUPAC Name | 10-[(3-aminophenyl)methyl]-7-methyl-4-methylsulfinyl-3-thia-7,10,11-triazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),4,11-tetraen-9-one |
INCHI | InChI=1S/C17H16N4O2S2/c1-20-13-7-14(25(2)23)24-16(13)12-8-19-21(17(22)15(12)20)9-10-4-3-5-11(18)6-10/h3-8H,9,18H2,1-2H3 |
InChi Key | ZWKJWVSEDISQIS-UHFFFAOYSA-N |
Canonical SMILES | CN1C2=C(C3=C1C(=O)N(N=C3)CC4=CC(=CC=C4)N)SC(=C2)S(=O)C |
Isomeric SMILES | CN1C2=C(C3=C1C(=O)N(N=C3)CC4=CC(=CC=C4)N)SC(=C2)S(=O)C |
PubChem CID | 44246499 |
分子量 | 372.5 |
溶解性 | Soluble in DMSO (~10 mg/ml). |
---|---|
密度 | ~1.6 g/cm3(Predicted) |
折光率 | n20D1.81 (Predicted) |
沸点 | ~711.6° C at 760 mmHg (Predicted) |
分子量 | 372.500 g/mol |
XLogP3 | 1.300 |
氢键供体数Hydrogen Bond Donor Count | 1 |
氢键受体数Hydrogen Bond Acceptor Count | 6 |
可旋转键计数Rotatable Bond Count | 3 |
精确质量Exact Mass | 372.071 Da |
单同位素质量Monoisotopic Mass | 372.071 Da |
拓扑极表面积Topological Polar Surface Area | 128.000 Ų |
重原子数Heavy Atom Count | 25 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 601.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 1 |
定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 0 |
共价键合单元计数Covalently-Bonded Unit Count | 1 |
Appearance(M333473) | White to off white to yellow solid |
---|---|
Purity(HPLC) | 98-100(%) |
Proton NMR spectrum | Conforms to structure |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
批号(Lot Number) | 证书类型 | 日期 | 货号 |
---|---|---|---|
![]() |
分析证书 | 23-02-28 | M333473 |
![]() |
分析证书 | 23-02-28 | M333473 |
![]() |
分析证书 | 23-02-28 | M333473 |
![]() |
分析证书 | 23-02-28 | M333473 |
![]() |
分析证书 | 23-02-28 | M333473 |
![]() |
分析证书 | 23-02-28 | M333473 |
![]() |
分析证书 | 23-02-28 | M333473 |
![]() |
分析证书 | 23-02-28 | M333473 |
![]() |
分析证书 | 23-02-28 | M333473 |
![]() |
分析证书 | 23-02-28 | M333473 |
1. Fan F, Wood KV. (2007) Bioluminescent assays for high-throughput screening.. Assay Drug Dev Technol, 5 (1): (127-36). [PMID:17355205] [10.1021/op500134e] |
2. Jiang JK, Boxer MB, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, Park HW et al.. (2010) Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.. Bioorg Med Chem Lett, 20 (11): (3387-93). [PMID:20451379] [10.1021/op500134e] |
3. Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A et al.. (2012) Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis.. Nat Chem Biol, 8 (10): (839-47). [PMID:22922757] [10.1021/op500134e] |
4. Jiang J, Walsh MJ, Brimacombe KR, Anastasiou D, Yu Y, Israelsen WJ, Hong BS, Tempel W, Dimov S, Veith H et al.. (2010) ML265: A potent PKM2 activator induces tetramerization and reduces tumor formation and size in a mouse xenograft model. Probe Reports from the NIH Molecular Libraries Program, 71 (13): (1755-70). [PMID:23905203] [10.1021/op500134e] |
5. Angiari S, Runtsch MC, Sutton CE, Palsson-McDermott EM, Kelly B, Rana N, Kane H, Papadopoulou G, Pearce EL, Mills KHG et al.. (2020) Pharmacological Activation of Pyruvate Kinase M2 Inhibits CD4+ T Cell Pathogenicity and Suppresses Autoimmunity.. Cell Metab, 31 (2): (391-405.e8). [PMID:31761564] [10.1016/j.cmet.2019.10.015] |